Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$19.67 USD

19.67
4,324,041

+0.84 (4.46%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $19.68 +0.01 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Gilead's (GILD) Breast Cancer Drug Trodelvy Gets FDA Nod

by Zacks Equity Research

Gilead Sciences, Inc. (GILD) announces the FDA approval of their first-in-class, Trop-2 directed antibody-drug conjugate, Trodelvy, for the treatment of metastatic HR+/HER2- breast cancer in adult patients.

Karuna (KRTX) to Obtain Global Rights to Goldfinch's Candidates

by Zacks Equity Research

Karuna Therapeutics (KRTX) announces a definitive agreement with Goldfinch Bio to acquire global rights to the latter's lead clinical-stage candidate, GFB-887 and TRPC4/5 channel candidates.

Biomea (BMEA) Begins Dosing in Lung Cancer Study, Stock Up

by Zacks Equity Research

Biomea Fusion (BMEA) announces the successful dosing of the first patient in phase I/Ib study of BMF-219 in KRAS mutant solid tumors. Stocks rise 11.69% in response.

Adma Biologics (ADMA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of 0% and 18.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -10% and 7.73%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Adma Biologics (ADMA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of 22.22% and 8.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cyclerion Therapeutics, Inc. (CYCN) delivered earnings and revenue surprises of 8.82% and 56.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adma Biologics (ADMA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of 7.14% and 19.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 10.98% and 12.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of -25% and 9.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of 65.64% and 34.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of 10% and 1.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for ADMA Biologics (ADMA) Stock Options

by Zacks Equity Research

Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.

Community Health (CYH) Up 64% YTD: More Growth Potential Left?

by Zacks Equity Research

Community Health Systems' (CYH) cost-control initiatives are likely to lower costs to a great extent and boost the bottom line.

Benjamin Rains headshot

Find Strong Cheap Stocks Under $10 to Buy in December

by Benjamin Rains

Given this backdrop, investors likely want to consider adding stocks in December and heading into 2022. Today, we utilized a Zacks screen to find highly-ranked stocks trading for under $10 a share...

Adma Biologics (ADMA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of 13.33% and 11.29%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Emergent (EBS) Q3 Earnings Miss, Contract Revenue View Down

by Zacks Equity Research

Emergent's (EBS) third-quarter 2021 earnings and sales miss estimates. The company tightens the revenue guidance on lower anticipated revenues from the CDMO segment. Stock down in after-market trading.

Will Adma Biologics (ADMA) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adma Biologics (ADMA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of 0.00% and 7.73%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Adma Biologics (ADMA) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bionano (BNGO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Bionano Genomics (BNGO) is expected to provide updates on its earnings and revenues when it reports first-quarter 2021 result.

Why ADMA Biologics (ADMA) Might Surprise This Earnings Season

by Zacks Equity Research

ADMA Biologics (ADMA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Will Adma Biologics (ADMA) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.